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The relation between IL-10 gene (-1082G/A) 
and VEGF gene 936 C/T polymorphism and 
diabetic polyneuropathy in a cohort of 
Egyptian patients with type 2 diabetes
AbsTrACT 
background. Polymorphisms have been described to 
be correlated with type 2 diabetes mellitus (T2DM) and 
its complications including diabetic polyneuropathy 
(DPN). The aim of this study was to investigate the rela-
tion between interleukin (IL)-10-1082 G/A (rs1800896) 
and vascular endothelial growth factor (VEGF)-936 C/T 
polymorphisms and DPN in T2DM patients.
Methods. This cross-sectional study included 50 T2DM 
patients and 40 controls. Clinical and electrophysi-
ological assessments for DPN, fasting blood glucose 
level (Fbs) and glycosylated hemoglobin (HbA1C) were 
recorded. VEGF-936 C/T polymorphism was carried out 
by polymerase chain reaction-restriction fragment 
length polymorphism (PCr-rFLP) technique. Genotyp-
ing for IL-10 promotor gene (-1082 G/A) (rs1800896) 
polymorphism was performed using real-time PCr. 
Results. Sixty percent of patients had confirmed DPN, 
while none of them were considered normal. IL-10 
(genotype -1082G/G) was statistically higher among 
controls compared to T2DM patients (P = 0.008). 
VEGF-936-CT genotype was statistically higher among 
patients compared to controls (P = 0.033), but there 
was no significant relation between IL-10-1082 G/A 
or VEGF-936 C/T polymorphism genotypes and DPN. 
Patients with IL-10 (genotype-1082A/G) had higher 
HbA1c level (P = 0.041) and lower albumin/creatinine 
ratio, while those with IL-10 (genotype-1082G/G) had 
higher albumin/creatinine ratio (P = 0.024). Thus, DPN 
has significant correlation with the duration of diabe-
tes, Fbs and HbA1c.
Conclusion: The VEGF-936 C/T genotype may be as-
sociated with T2DM in contrast to IL-10 (genotype-
1082G/G) which may be less likely to be associated 
with it. However, there is no association between 
VEGF-936 or IL-10-1082 genotypes and DPN. (Clin 
Diabetol 2021; 10)
Key words: type 2 diabetes mellitus, polymorphism, 
interleukin-10, vascular endothelial growth factor, 
diabetic polyneuropathy, total neuropathy score 
Introduction
Type 2 diabetes mellitus (T2DM) is an immune-
mediated disease that leads to defective insulin signal-
ing and selective destruction of insulin producing beta 
cells in which cytokines play an important role in this 
destruction [1]. Diagnosis is usually delayed for many 
years, making the patients at higher risk for developing 
macro- and micro-vascular complications [2, 3].
Diabetic neuropathies (DNs) are among the most 
common long-term complications of diabetes which 
affect up to 50% of patients [4]. There are wide varie-
ties of DNs; the commonest one is the distal symmetric 
diabetic polyneuropathy (DPN) [5, 6].
Hyper-secretion of pro-inflammatory cytokines in 
overweight and obese individuals can cause insulin 
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resistance in peripheral tissues [7] and reduction of 
the mass and function of beta cells [8], contributing 
to T2DM development. Therefore, an imbalance in the 
activity of these cytokines may play an important role 
in T2DM pathogenesis. 
The production of cytokines is controlled geneti-
cally, and polymorphisms have been identified within 
a large number of these genes [9]. On the basis of 
genotype, there are ‘high’ and ‘low’ cytokine producers. 
By recognizing specific polymorphisms in each cytokine 
gene, it is possible to identify these high and low cy-
tokine producers by genotyping. Therefore, a genetic 
predisposition for a hyper-reactive immune response 
may be responsible for T2DM development. Moreover, 
the development of DPN and other complications may 
be associated with polymorphisms in cytokine genes 
[10, 11].
Interleukin (IL)-10 is an anti-inflammatory and 
immunosuppressive substance which plays a role in 
the control of immune responses [12]. IL-10 gene 
rs1800896 polymorphism (IL-10-1082G/A polymor-
phism) in the promoter region could influence IL-10 
gene expression [13]. This polymorphism has been 
described to be correlated with T2DM [14].
The vascular endothelial growth factor (VEGF) gene, 
located at chromosome 6p21.3, is involved in angio-
genesis modulation under physiologic and pathologic 
conditions. It has a role in proliferation, differentiation, 
migration and survival of cells, as well as nitric oxide 
production and release of other growth factors [15]. 
VEGF has been identified as the main mediator in 
the pathogenesis of cardiovascular complications in 
T2DM [16].
Therefore, the aim of the current study was to 
investigate the relation between IL-10 promoter gene 
-1082 G/A (rs1800896) and VEGF-936 C/T polymor-
phisms and DPN in a cohort of T2DM Egyptian patients.
Methods
subjects 
This cross-sectional study was conducted on 50 
patients with T2DM, who were attending the Endocrine 
and Physical Medicine, Rheumatology and Rehabilita-
tion outpatient clinics in Alexandria University Hospi-
tals, Alexandria, Egypt. These patients were diagnosed 
according to the guidelines of the American Diabetes 
Association [17]. Forty age- and sex-matched healthy 
individuals were included as a control group. The study 
was conducted over a period of 1 year.
Patients with T2DM were excluded if they were 
on thiazolidinedione or received it in the previous 
three months. Patients with a history of the following 
conditions were also excluded from the study: type I 
diabetes, recent acute infection, autoimmune diseases, 
endocrine disorders with secondary diabetes, as well as 
history of acute pancreatitis, acute or chronic hepatitis 
B or C, human immunodeficiency virus and malignant 
disease within the past five years. Patients on long-term 
treatment with immunosuppressive, immunomodula-
tory and anti-inflammatory drugs as well as certain 
anti-depressants and drugs with possible pro-diabetic 
effects as glucocorticoids were also excluded. 
In the control group, T2DM was excluded based 
on the fasting blood glucose (FBS) (7 mmol/L) and 
glycosylated hemoglobin (HbA1c) (< 6.5%).
Clinical and laboratory evaluation: All partici-
pants were subjected to full history taking and physical 
examination. Detailed medical history (age at diabetes 
diagnosis, duration of T2DM, medication history and 
history of complications) was recorded and body mass 
index (BMI) was calculated. Diabetic retinopathy was 
evaluated by direct fundoscopy under mydriasis. FBS, 
HbA1c and albumin/creatinine ratio were recorded.
Diabetic polyneuropathy assessment
Diabetic polyneuropathy was evaluated by neurologi-
cal examination [18] and nerve conduction study (NCS) of 
both lower limbs [19]. The total neuropathy score-reduced 
(TNS-r), a combined clinical and electrophysiological score, 
was used to calculate DPN severity [20].
NCS was considered abnormal: if the abnormality 
was ≥ 1 in 2 separate nerves [21].
Categorization of patients according to DPN was as 
follows: patients with no clinical or electrophysiological 
evidence of neuropathy were categorized as normal, 
those with clinical signs or symptoms of neuropathy 
were categorized as possible clinical DPN, those with 
a combination of clinical signs and symptoms of neu-
ropathy were categorized as probable clinical DPN, 
those with neither clinical signs nor symptoms of neu-
ropathy but with abnormal NCS were categorized as 
subclinical DPN and those with a combination of clinical 
signs and symptoms of neuropathy plus abnormal NCS 
were categorized as confirmed DPN [22, 23].
blood sample collection: Peripheral blood sam-
ples were obtained by venipuncture using a sterile 
aseptic technique using EDTA vacutainer tubes. About 
5 milliliters of venous blood were withdrawn.
Genotyping: Total genomic deoxyribonucleic acid 
(DNA) was purified according to the manufacturer 
protocol using the QIAamp DNA Blood Mini Kit, (QIA-
GEN, Germany). DNA quantity and purity were assayed 
using a Nanodrop 2000 spectrophotometer (Thermo 
Scientific, USA). The A260:A230 ratio greater than 1.6 
and A260:280 ratio greater than 1.8 were considered 
as indicators for highly pure DNA.
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VEGF-936 C/T single nucleotide polymorphism 
(SNP) genotyping was carried out by polymerase chain 
reaction-restriction fragment length polymorphism 
(PCR-RFLP) technique. DNA amplification using PCR 
technique was first performed using Thermo Scientific 
DreamTaq Green master mix with a final volume of 20 
μl. The PCR reaction was carried out on the Simpli-
Amp Thermal Cycler (Applied Biosystems, USA). Two 
sequence-specific primers were used for the targeted 
fragment of VEGF gene. The PCR primers were: [24]
Forward: 5’-AAG GAA GAG GAG ACT CTG CGC3.’
Reverse: 5’- TAT GTG GGT GGG TGT GTC TAC AGG-3.’
The PCr cycling conditions was as follows: 
initial denaturation for 1 cycle at 95ºC for 2 minutes, 
followed by 35 cycles at 95ºC for 30 seconds, 62ºC for 
30 seconds, 72ºC for 60 seconds and final extension 
for 1 cycle at 72ºC for 10 minutes. A PCR product of 
198 base pairs (bp) was generated. The amplified PCR 
products were digested with NlaIII enzyme with buffer 
G 10X (Thermo Scientific) at 37ºC for 120 minutes 
followed by 65oC for 20 mins. Digested product and 
marker were analyzed in 2% agarose gel electropho-
resis. After the electrophoresis process (110 V for 30 
minutes), the result was photographed and analyzed. 
Digested products were (Fig. 1):
1) CC genotype: 1 band with product length of 198 bp
2) CT genotype: 3 bands with product length of 198 bp, 
114 bp, and 84 bp
3) TT genotype: 2 bands with product length of 114 
bp and 84 bp.
Genotyping for IL-10 promotor gene 1082 G/A 
polymorphism (rs1800896) was performed using 
real time PCR (TaqMan genotyping assay). The PCR 
reaction mix contained 10 ul TaqMan Universal 
PCR Master Mix (Applied Biosystems, USA), 0.5ul 
of TaqMan SNP Genotyping Assay 20X (Assay ID 
C___1747360_10), 20 ng DNA/reaction, and DNase 
free water to final volume of 20 ul. Thermal cycling 
was done using Stratagene as follows: initial Am-
pliTaq enzyme activation at 95oC for 10 minutes, 
40 cycles of denaturation at 95oC for 15 seconds and 
annealing/extension at 60oC for 1 minute.
Ethical consideration
This research was conducted on human partici-
pants in accordance with the ethical standards of local 
ethical committee on human experimentation and Hel-
sinki Declaration of 1964 and later versions. The study 
was approved by the Ethics Committee of Alexandria 
University, Egypt (serial number: 0304298-18/04/2019). 
A written informed consent was obtained from all 
participants enrolled in this study. 
statistical analysis
Data were analyzed using IBM SPSS software 
package version 20.0. Comparison between different 
groups regarding categorical variables was tested using 
chi square (c2) test. The distributions of quantitative 
variables were tested for normality using Kolmogorov–
Smirnov test. Normally distributed data were expressed 
using mean ± standard deviation and compared using 
independent t test (between two groups) or one-way 
ANOVA (three or more groups). Abnormally distributed 
data were described using minimum, maximum, and 
median and compared using Mann-Whitney test (be-
tween two groups) or Kruskal-Wallis H test (three or 
more groups). Statistical significance was considered at 
P < 0.05. Genotype frequencies were compared with 
Hardy-Weinberg equilibrium (HWE) using c2 test. If 
P > 0.05, this means that the observed frequencies 
do not significantly differ from those expected and 
thus, the population is in HWE. Odds ratio was used 
Figure 1. Electrophoresis of Digested PCR Product. CC genotype consists of 1 band (198 bp), CT genotype consists of 3 bands 
(198 bp, 114 bp, and 84 bp) and TT genotype consists of 2 bands (114 bp and 84 bp). Marker 100 bp on lane 1
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to quantify the degree of relation between exposure 
(genotype/allele) and outcome (patient status).
Power calculation
A sample size of 90 achieves 85% power to detect 
a medium effect size (W) of 0.35 in VGEF genotype 
between patients with DPN and controls using 2 de-
grees of freedom Chi-Square test with a significance 
level (alpha) of 0.05, according to Barus et al. in 2018 
[25]. The sample size was calculated using NCSS 2004/
PASS 2000 software.
Results
This cross-sectional study was conducted on 50 
patients with T2DM collected over a period of 1 year 
and 40 healthy age- and sex-matched individuals. Most 
participants in both groups were middle-aged, obese 
and housewife females. There was no statistically sig-
nificant difference between the 2 groups regarding the 
demographic data (Table 1).
The mean duration of T2DM was 9.58 ± 6.88 years. 
Thirty five patients (70%) were on oral hypoglycemic 
drugs, 14 patients (28%) were on combined oral hypo-
glycemic drugs and insulin therapy and only 1 patient 
was not medicated, he just was on diet control and 
exercise. Fourteen patients (28%) had no associated 
conditions while 30 patients (60%) had associated 
conditions. The most common associated conditions 
were musculoskeletal complains in 17 patients (34%) 
in the form of muscle cramps, knee osteoarthritis and 
shoulder periarthritis, followed by hypertension in 12 
patients (24%) and gout in 8 patients (16%). The least 
common associated conditions were hypothyroidism 
in 2 patients (4%) and fatty liver with elevated liver 
enzymes in 1 patient (2%). Only 3 patients (6%) had 
serious associated medical conditions in the form of 
muscle weakness in both lower limbs with difficulty 
in walking, stroke with consequent hemiplegia and 
myocardial infarction. Non-proliferative diabetic retin-
opathy was found in 14 patients (28%). 
Distribution of patients according to diabetic 
polyneuropathy
Neurological symptoms, signs of DPN or a com-
bination of both were found in 48 patients (96%), 
while 33 patients (66%) had abnormal NCS and the 
mean TNS-r was 9.44 ± 5.90 ranging from 1–22. 
Most patients (n = 30) (60%) had confirmed DPN, 10 
patients (20%) had probable clinical DPN, 8 patients 
(16%) had possible clinical DPN and only 2 patients 
(4%) had subclinical DPN. None of the patients was 
considered normal.
Distribution of patients according to genetic 
polymorphisms:
Regarding the studied genetic polymorphisms, 
patients with T2DM showed a higher frequency of 
IL-10 (genotype -1082A/G) genotype in comparison 
to controls (60% vs. 42.5% P = 0.099); however, this 
was not statistically significant. The GG genotype was 
statistically higher among controls compared to T2DM 
patients (P = 0.008). The frequency of IL-10–1082 A 
Allele was higher among patients compared to controls 
(60% vs. 46.3%, P = 0.066), but this was not statisti-
cally significant (Table 2).
Moreover, T2DM patients showed a statically sig-
nificant higher frequency of VEGF-936 C/T genotype 
compared to controls (44% vs. 22.5%, P = 0.033). 
Table 1. Comparison between the two studied groups according to demographic data 
Patients (n = 50) Control (n = 40) Test of sig. P
Age (years)
Mean ± SD 52.96 ± 10.75 49.83 ± 9.44 t = 1.450 0.151
Sex
Male 16 (32%) 18 (45%) χ2 = 1.598 0.206
Female 34 (68%) 22 (55%)
Occupation
Housewife 26 (52%) 23 (57.5%) χ2 = 6.580 MCP = 0.085
Worker 9 (18%) 13 (32.5%)
Desk job 8 (16%) 2 (5%)
Retired 7 (14%) 2 (5%)
BMI (kg/m2)
Mean ± SD 33.24 ± 5.97 34.40 ± 5.45 t = 0.953 0.343
c2: Chi square test; MC: Monte Carlo test; t: Student t-test; P: P value for comparing between the two groups; *: Statistically significant at P ≤ 0.05; SD: 
slandered deviation; BMI: body mass index 
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Also, they showed lower CC genotype frequency (52% 
vs. 70%, P = 0.083), but this was not statistically sig-
nificant. The frequency of T allele was higher among 
patients than controls, but this was not statistically 
significant (26% vs 18.8%, P = 0.652) (Table 2).
The genotype distribution of IL-10-1082 polymor-
phism conformed to HWE in both groups (P = 0.07 for 
patients and P = 0.358 for controls). Also, the genotype 
distribution of VEGF-936 C/T genotype conformed to 
HWE in both groups (P = 0.310 for patients and P = 
0.098 for controls) (Table 2).
relation between diabetic polyneuropathy  
and genetic polymorphisms
In order to investigate if the described relation 
between either IL-10-1082 gene genotype (rs1800896) 
or VEGF-936 genotype and DPN was a consequence of 
other risk factors (phenotype characteristics), an analy-
sis of the studied groups with different genotypes was 
performed in relation to sex, age and anthropometric 
characteristics. There was no statistically significant 
difference between subjects with different genotypes 
for the IL-10-1082 G/A (rs1800896) and VEGF-936 C/T 
polymorphisms in terms of age, sex, or BMI. 
Patients showing IL-10 (genotype -1082A/A) or 
VEGF (genotype -936 T/T) showed a higher TNS-r 
score, but this was statistically insignificant (H = 3.423, 
P = 0.181, H = 0.289, P = 0.868, respectively) 
(Tables 3, 4). 
Relation between other diabetic traits 
and genetic polymorphisms:
There were significantly lower HbA1c and albu-
min/creatinine ratio among patients showing IL-10 
(genotype-1082A/G) compared to the other genotypes 
(P = 0.041 and P = 0.024 respectively), while the 
homozygous GG genotype had a significantly higher 
albumin/creatinine ratio (Table 3). On the other hand, 
no significant relations were found between the differ-
ent diabetic traits and different VEGF-936 genotypes 
(Table 4).
Correlation between diabetic polyneuropathy 
and other diabetic factors
Patients with non-proliferative diabetic retinopathy 
had statistically higher TNS compared to patients with 
normal vessels and disc on fundus examination [12 
(7–22) and 9 (1–22), respectively], with a statistically 
significant difference between the two groups (U = 
155.5, P = 0.036). Also, there was a very high statisti-
cally significant positive correlation between TNS and 
the duration of diabetes (rs = 0.721, P < 0.001), FBS 
(rs = 0.548, P < 0.001) and HbA1c levels (rs = 0.581, 
P < 0.001).
Discussion
The strong influence of ethnic differences on ge-
netic predisposition of multifactorial diseases highlights 
the importance of regional studies that present a chan-
Table 2. Comparison between the two studied groups according to IL-10 and VEGF genotypes
Patients Control c2 p Or 95% CI (LL – UL)
IL-10-1082 gene (n = 50) (n = 40)
GG 5 (10%) 13 (32.5%) 7.031* 0.008* 0.231 0.074–0.719
AG 30 (60%) 17 (42.5%) 2.728 0.099 2.029 0.872–4.723
AA 15 (30%) 10 (25%) 0.277 0.599 1.286 0.504–3.282
Allele frequency (n = 100) (n = 80)
A 60 (60%) 37 (46.3%) 3.382 0.066 1.743 0.962–3.16
G 40 (40%) 43 (53.8%) 0.574 0.317–1.039
P for Hardy 0.077 0.358
VEGF gene (n = 50) (n = 40)
CC 26 (52%) 28 (70%) 3.0 0.083 0.464 0.194–1.114
CT 22 (44%) 9 (22.5%) 4.549* 0.033* 2.706 1.069–6.851
TT 2 (4%) 3 (7.5%) 0.519 FEP = 0.652 0.514 0.082–3.235
Allele frequency (n = 100) (n = 80)
C 74 (74%) 65 (81.3%) 1.328 0.249 0.657 0.321–1.346
T 26 (26%) 15 (18.8%) 1.523 0.743–3.120
P for Hardy 0.310 0.098
IL: interleukin, VEGF: vascular endothelial growth factor, c2: Chi square test, FE: Fisher Exact  
P: P value for comparing between the two groups; *: Statistically significant at p ≤ 0.05
LL: Lower limit; UL: Upper limit; CI: Confidence interval. If P < 0.05 — not consistent with HWE (Hardy-Weinberg)
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nel for a greater understanding of the pathogenesis 
and improvement of prevention and treatment of 
these diseases. 
In this cross-sectional study, we analyzed the as-
sociation between IL-10 gene (-1082G/A) rs1800896 
and VEGF-936 C/T polymorphisms and DPN in a group 
of Egyptian patients with T2DM. Although the sample 
size used in this study is smaller than that usually used 
for gene polymorphism studies, the power calculation 
showed a medium effect size supporting the validity 
of the study results. 
Regarding IL-10 gene (-1082G/A) polymorphism 
(rs1800896), our current study has shown higher frequen-
cy of the AG genotype among patients (60%) compared 
to controls (42.5%) but with no statistical significance. 
The IL-10 GG genotype was statistically higher among the 
included controls compared to T2DM patients. In a review 
and meta-analysis by Hua et al. in 2013 [26], a significant 
association between IL-10-1082 G/A polymorphism and 
the risk of T2DM was observed under heterozygote com-
parison (GA vs. AA: OR = 1.21, 95% CI = 1.03–1.14) and 
dominant genetic model (GA/GG vs. AA: OR = 1.22, 95% 
CI = 1.05–1.41). In the stratified analysis by ethnicity, 
IL-10 gene (-1082G/A) polymorphism (rs1800896) was 
associated with a significantly increased risk of T2DM in 
Asian descendants under dominant genetic model (GA/
GG vs. AA: OR = 1.69, 95% CI = 1.21–2.38). However, no 
significant association was found in European or African 
descendants [26]. This controversy may be attributed 
to the racial and ethnic differences. This is consistent 








Test of sig. P
TNS-r
Mean ± SD. 11.67 ± 5.56 8.38 ± 5.43 9.2 ± 8.76 H = 3.423 0.181
Median (Min.–Max.) 12 (2-22) 9 (1–20) 10 (1–22)
HbA1c
Mean ± SD. (%) 9.13 ± 1.85 7.61a ± 1.80 7.84 ± 2.16 F = 3.422* 0.041*
Median (Min.–Max.) (%) 9 (6–12.7) 7.1 (5.4–11.9) 9 (5.1–10.1)
Median (Min.–Max.) (mmol/mol) 75 (42–115) 54 (36–107) 75 (32–87)
Albumin / Creatinine ratio
Mean ± SD 102.79 ± 111.8 67.71a ± 168.90 171.82b ± 296.08 H = 7.424* 0.024*
Median (Min.–Max.) 55 (2.2–400) 5.65 (2–700) 50 (2–700)
F: F for ANOVA test; H: H for Kruskal Wallis test; P: P value for comparing between the studied categories; *: Statistically significant at P ≤ 0.05; IL: interleu-
kin; HbA1c: glycosylated hemoglobin; TNS-r: total neuropathy score-reduced








Test of sig. P
TNS
Mean ± SD. 9.5 ± 5.13 9.14 ± 6.29 12 ± 14.14 H = 0.289 0.868
Median (Min.–Max.) 10 (1–21) 9.5 (1–22) 12 (2–22)
HbA1C
Mean ± SD. (%) 8 ± 1.93 8.16 ± 1.93 8.45 ± 3.46 F = 0.074 0.929
Median (Min.–Max.) (%) 7.75 (5.1–11.9) 8.1 (5.6–12.7) 8.45 (6–10.9)
Median (Min.–Max.) (mmol/mol) 61.2 (32–107) 65 (37.7–115) 68.9 (42.1–95.6)
Albumin/Creatinine ratio
Mean ± SD. 74.14 ± 148.52 106.92 ± 198.58 76.10 ± 104.51 H = 0.063 0.969
Median (Min.–Max.) 10.1 (2–700) 12.5 (2–700) 76.1 (2.2–150)
F: F for ANOVA test; H: H for Kruskal Wallis test; P: P value for comparing between the studied categories; *: Statistically significant at P ≤ 0.05; VEGF: vascu-
lar endothelial growth factor; HbA1c: glycosylated hemoglobin; TNS-r: total neuropathy score-reduced
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with another study which evaluated the role of this 
polymorphism with diabetic retinopathy [27]. The direct 
association of the IL-10 gene (-1082G/A) polymorphism 
(rs1800896) with T2DM remains elusive. The results of 
a meta-analysis published in 2013, which included 10 
studies, demonstrated that the IL-10 gene (-1082G/A) 
polymorphism (rs1800896) was clearly associated with 
T2DM, but only in the Asian population, not in the Euro-
pean or African populations [26].
In a study performed by Kolla et al. in 2009 [10], 
the development of DPN was associated with high 
production of IL-10 (genotype -1082G/G) which is 
contrary to our study that showed no significant as-
sociation between this polymorphism and DPN among 
cases with T2DM. However, our study showed a sig-
nificant association between IL-10-1082 polymorphism 
(rs1800896) and the albumin/creatinine ratio, suggest-
ing a possible association between this polymorphism 
and diabetic nephropathy. Nonetheless, further analysis 
on a wider scale with more specific and accurate inves-
tigations is needed to evaluate the role of IL-10-1082 
polymorphism(rs1800896) in diabetic nephropathy. 
Other studies evaluated the role of this polymorphism 
in relation to other micro-vascular complications such 
as retinopathy, showing that IL-10 gene rs1800896 
polymorphism is associated with a decreased risk of 
proliferative diabetic retinopathy [27].
Regarding the VEGF gene 936 C/T polymorphism, 
the frequency of CC genotype among patients was 52% 
compared to 70% among controls. In addition, the CT 
genotype was significantly higher among patients (44%) 
compared to controls (22.5%). This finding disagrees with 
the study of Ghisleni et al. in 2015 [28] in which no sta-
tistical significance was found between the two groups. 
Hardy-Weinberg analysis showed a p value of 0.098 
meaning that the genotype frequency fulfilled the HWE.
The studies focusing on the expression of VEGF 
in diabetes patients with neuropathic complications 
exhibit contradictory findings [29-32]. Our study didn’t 
find any statistical association between VEGF-936 C/T 
polymorphism and DPN. Another study performed by 
Kim et al. in 2009 [31] also demonstrated that there 
was no significant relationship between VEGF gene 
936 C/T polymorphism and DPN. However, a study by 
Tavakkoly-Bazzaz et al. in 2010 [32] suggested that 
allele C was considered probably related to increased 
risk of developing DPN, while allele T might be protec-
tive [32]. The exact role of VEGF gene 936 C/T poly-
morphism in DPN remains controversial. Nonetheless, 
other studies evaluated the role of this SNP with other 
microvascular complications in patients with T2DM and 
their results showed that the TT genotype was more 
frequent among T2DM patients with retinopathy [31].
 The significant correlation between TNS-r and 
other important diagnostic and therapeutic traits in 
diabetes as the duration of diabetes, FBS and HbA1c 
along with the fact that all T2DM patients included in 
this study had a grade of DPN and none was considered 
normal supports the importance of tight glycemic con-
trol to protect against this complication and delay its 
onset and severity [33]. Also, the presence of a grade 
of DPN in patients with short duration of diabetes 
(less than 3 years of diagnosis), even if considered 
subclinical, supports the reports demonstrating that 
the diagnosis of T2DM is usually delayed for many years 
due to the gradual onset of symptoms [2].
Conclusion
The VEGF 936 C/T genotype may be associated with 
T2DM, while the IL-10-GG genotype may be less likely to 
be associated with it; however, there is no association 
between VEGF-936 or IL-10 genotypes and DPN. The 
different traits showed different importance in T2DM-
related traits, while DPN is correlated with the most 
important prognostic and disease monitoring traits of 
diabetes. When considering the results of other studies, 
a substantial heterogeneity in the findings is observed, 
demonstrating a complex link between T2DM risk fac-
tors and genetic predisposition. Such complexity can 
be explained largely by the variability in ethnicity of the 
studied populations and the influence of environmental 
factors on genetic expression.
study limitations
Further studies regarding other genetic variants 
related to glycemic and metabolic function, ethnicity, 
especially the ones presumably related to nerve struc-
ture and function are needed to detect the strongest 
genetic factors associated with DPN. Also, population-
based studies are recommended to help elucidating the 
role of these polymorphisms in T2DM complications. 
In addition, since this is a cross-sectional study, the 
disease outcome and prognosis in relation to a specific 
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